Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 302

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 302
---
, is its stated value of $ 279 (June 30, 2023 - $ 279 ).

There was no change to the Series A Preferred stock for the six months ended December 31, 2023, or 2022.

Common stock

Common stock issuances during the six months ended December 31, 2023

On September 19, 2023, the Company entered into a Sales Agreement, (the “Sales Agreement”) with A.G.P./Alliance Global Partners (the “Agent”) pursuant to which the Company may offer and sell, from time to

<div align='center'>F-5 9</div>

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted) time, through the Agent, as sales agent and/or principal, shares of common stock having an aggregate offering price of up to $ 2.85million (the “ATM Facility”), subsequently increased to $ 10.9million on December 18, 2023. From October 31, 2023, until December 31, 2023, the Company raised $ 2,579in net proceeds, after deducting share issuance costs of $ 97, from the sale of 8,013shares of its common stock at a weighted average price of $ 0.33per share under the ATM Facility. As of December 31, 2023, the Company has collected net proceeds of $ 2.5million for the issuance of 7,430shares of common stock and the remaining $ 103million of net proceeds for the issuance of 581shares of common stock are recorded as subscriptions receivable. During the six months ended December 31, 2023, the Company sold 400shares of common stock at a weighted average price of $ 0.23per share for total net proceeds of approximately $ 105under the Purchase Agreement with Lincoln Park. During the six months ended December 31, 2023, the Company issued 4shares of common stock on vesting of restricted stock units during the period. Common stock issuances during the six months ended December 31, 2022 On August 2, 2022, the Company entered into a stock purchase agreement, dated as of August 2, 2022, (the “Purchase Agreement”)